Mohseni, Morvarid
1Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
12 papers on CoChatORCID 0000-0002-0964-924X
Most cited papers
- Verified
Yap1 acts downstream of α-catenin to control epidermal proliferation
Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszak, J., Rodriguez, J. R., Zhou, D., Kreger, B. T., Vasioukhin, V., Avruch, J., Brummelkamp, T. R., et al. (2011) · Cell
Hippo pathway signaling and YAP/TAZHair Growth and Disorders
Cited by 1,036
- Verified
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine
RNA Interference and Gene DeliveryCytokine Signaling Pathways and Interactions
Cited by 445
- Verified
Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis
Cai, Z., Kotzin, J. J., Ramdas, B., Chen, S., Nelanuthala, S., Palam, L. R., Pandey, R., Mali, R. S., Liu, Y., Kelley, M. R., et al. (2018) · Cell Stem Cell
Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation
Cited by 394
- Verified
Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer
Mori, M., Triboulet, R., Mohseni, M., Schlegelmilch, K., Shrestha, K., Camargo, F. D., & Gregory, R. I. (2014) · Cell
Hippo pathway signaling and YAP/TAZMicroRNA in disease regulation
Cited by 335
- Verified
A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway
Mohseni, M., Sun, J., Lau, A., Curtis, S., Goldsmith, J., Fox, V. L., Wei, C., Frazier, M., Samson, O., Wong, K.-K., et al. (2014) · Nature Cell Biology
Hippo pathway signaling and YAP/TAZMicrotubule and mitosis dynamics
Cited by 294
- Verified
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 231
- Verified
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
LaRochelle, J. R., Fodor, M., Vemulapalli, V., Mohseni, M., Wang, P., Stams, T., LaMarche, M. J., Chopra, R., Acker, M. G., & Blacklow, S. C. (2018) · Nature Communications
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 167
- Verified
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 167
- Verified
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Lu, H., Liu, C., Velazquez, R., Wang, H., Dunkl, L. M., Kazic-Legueux, M., Haberkorn, A., Billy, E., Manchado, E., Brachmann, S. M., et al. (2019) · Molecular Cancer Therapeutics
Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways
Cited by 90
- Verified
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
Sarver, P., Acker, M., Bagdanoff, J. T., Chen, Z., Chen, Y.-N., Chan, H., Firestone, B., Fodor, M., Fortanet, J., Hao, H., et al. (2019) · Journal of Medicinal Chemistry
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 87
- Verified
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Wang, Y., Mohseni, M., Grauel, A., Diez, J. E., Guan, W., Liang, S., Choi, J. E., Pu, M., Chen, D., Laszewski, T., et al. (2021) · Scientific Reports
Protein Tyrosine PhosphatasesCancer Immunotherapy and Biomarkers
Cited by 73
- Verified
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics
Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling
Cited by 53
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free